α1-antitrypsin deficiency: What has it ever done for us?

Chest

Volumn 144, Issue 6, 2013, Pages 1923-1929

  Stockley, Robert A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; LEUKOCYTE ELASTASE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DISEASE MODEL; DISEASE PREDISPOSITION; EMPHYSEMA; FORCED EXPIRATORY VOLUME; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HUMAN; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SMOKING; TISSUE INJURY;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; DISEASE MODELS, ANIMAL; EMPHYSEMA; GENETIC PREDISPOSITION TO DISEASE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNATIONAL COOPERATION; LUNG; PEPTIDE HYDROLASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84890275802     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1901     Document Type: Article

References (81)

1. Laurell C, Eriksson S. The electrophorectic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;15:132-140.
2. Snider GL. Emphysema: the first two centuries - and beyond. A historical overview, with suggestions for future research: part 1. Am Rev Respir Dis. 1992;146(5 pt 1):1334-1344.
3. Briscoe WA. Introductory remarks. In: C. Mittman, ed. Pulmonary Emphysema and Proteolysis. New York, NY: Academic Press; 1972:3-5.
4. Reid L. The Pathology of Emphysema. Philadelphia, PA: Lippincott; 1967.
5. Larson RK, Barman ML, Kueppers F, Fudenberg HH. Genetic and environmental determinants of chronic obstructive pulmonary disease. Ann Intern Med. 1970;72(5):627-632.
6. Kueppers F, Miller RD, Gordon H, Hepper NG, Offord K. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med. 1977;63(3):336-342.
7. Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis. 1977;116(3):469-475.
8. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055-1062.
9. Schluchter MD, Stoller JK, Barker AF, et al. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 2000;161(3 pt 1):796-801.
10. Brantly ML, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988;84(6A):13-31.
11. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357(6379):605-607.
12. Lomas DA, Belorgey D, Mallya M, et al. Polymerisation underlies alpha1-antitrypsin deficiency, dementia and other serpinopathies. Front Biosci. 2004;9:2873-2891.
13. Mallya M, Phillips RL, Saldanha SA, et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem. 2007;50(22):5357-5363.
14. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75(5):397-415.
15. Stockley RA, Dirksen A, Stolk J. Alpha-1 antitrypsin deficiency: the European experience. COPD. 2013;10(suppl 1):50-53.
16. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1345-1353.
17. Stolk J, Stockley RA, Stoel BC, et al. Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor. Eur Respir J. 2012;40(2):306-312.
18. Wood AM, Needham M, Simmonds MJ, Newby PR, Gough SC, Stockley RA. Phenotypic differences in alpha 1 antitrypsin-deficient sibling pairs may relate to genetic variation. COPD. 2008;5(6):353-359.
19. Dowson LJ, Guest PJ, Hill SL, Holder RL, Stockley RA. Highresolution computed tomography scanning in α1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J. 2001;17(6):1097-1104.
20. Stolk J, Cooper BG, Stoel B, et al. Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments. Ther Adv Respir Dis. 2010;4(6):319-332.
21. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001;164(10 pt 1):1805-1809.
22. Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1338-1344.
23. Wood AM, Harrison RM, Semple S, Ayres JG, Stockley RA. Outdoor air pollution is associated with rapid decline of lung function in alpha-1-antitrypsin deficiency. Occup Environ Med. 2010;67(8):556-561.
24. Parr DG, Stoel BC, Stolk J, Stockley RA. Validation of computed tomographic lung densitometry for monitoring emphysema in α1-antitrypsin deficiency. Thorax. 2006;61(6):485-490.
25. Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in a 1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004;170(11):1172-1178.
26. Holme J, Stockley RA. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency. Chest. 2007;132(3):909-915.
27. Holme J, Stockley JA, Stockley RA. Age related development of respiratory abnormalities in non-index α-1 antitrypsin deficient studies. Respir Med. 2013;107(3):387-393.
28. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1998;158(1):49-59.
29. Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10(10):2260-2263.
30. Wencker M, Fuhrmann B, Banik N, Konietzko N; Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119(3):737-744.
31. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. 2009;6(3):177-184.
32. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 pt 1):1468-1472.
33. Parr DG, Sevenoaks M, Deng C, Stoel BC, Stockley RA. Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; methodological advances. Respir Res. 2008;9(1):21.
34. Parr DG, Stoel BC, Stolk J, Nightingale PG, Stockley RA. Influence of calibration on densitometric studies of emphysema progression using computed tomography. Am J Respir Crit Care Med. 2004;170(8):883-890.
35. Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency. Respir Res. 2009;10(75):75.
36. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res. 2010;11:136.
37. Chapman KR, Burdon JGW, Piitulainen E et al. IV alpha antitrypsin (A1AT) preserves lung density in homozygous alpha-1-antitrypsin deficiency (A1ATD): a randomized placebocontrolled trial. Am J Resp Crit Care Med. 2013;187:A6069.
38. Gooptu B, Lomas DA. Polymers and inflammation: disease mechanisms of the serpinopathies. J Exp Med. 2008;205(7):1529-1534.
39. Teckman JH. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy. COPD. 2013;10(10 suppl 1):35-43.
40. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A. 2000;97(4):1796-1801.
41. Travis J, Matheson NR. Properties of mutant forms of alphaproteinase inhibitor prepared by recombinant DNA technology. In: Taylor JC, Mittman C, eds. Pulmonary Emphysema and Proteolysis. Orlando, FL: Academic Press;1986:133-141.
42. Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med. 1983;309(12):694-698.
43. Johnson D, Travis J. The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem. 1979;254(10):4022-4026.
44. Gadek JE, Fells GA, Crystal RG. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. Science. 1979;206(4424):1315-1316.
45. Carp H, Miller F, Hoidal JR, Janoff A. Potential mechanism of emphysema: a 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci U S A. 1982;79(6):2041-2045.
46. Stone PJ, Calore JD, McGowan SE, Bernardo J, Snider GL, Franzblau C. Functional alpha 1-protease inhibitor in the lower respiratory tract of cigarette smokers is not decreased. Science. 1983;221(4616):1187-1189.
47. Boudier C, Pelletier A, Gast A, Tournier JM, Pauli G, Bieth JG. The elastase inhibitory capacity and the alpha 1-proteinase inhibitor and bronchial inhibitor content of bronchoalveolar lavage fluids from healthy subjects. Biol Chem Hoppe Seyler. 1987;368(8):981-990.
48. Afford SC, Burnett D, Campbell EJ, Cury JD, Stockley RA. The assessment of a 1 proteinase inhibitor form and function in lung lavage fluid from healthy subjects. Biol Chem Hoppe Seyler. 1988;369(9):1065-1074.
49. Morrison HM, Burnett D, Stockley RA. The effect of catalase and methionine-S-oxide reductase on oxidised alpha 1-proteinase inhibitor. Biol Chem Hoppe Seyler. 1986;367(5):371-378.
50. 1-proteinase inhibitor. Hoppe Seylers Z Physiol Chem. 1984;365(4):503-510.
51. 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin Sci (Lond). 1987;72(3):373-381.
52. MacNee W. Oxidants and COPD. Curr Drug Targets Inflamm Allergy. 2005;4(6):627-641.
53. Bowler RP, Barnes PJ, Crapo JD. The role of oxidative stress in chronic obstructive pulmonary disease. COPD. 2004;1(2):255-277.
54. Kindzelskii AL, Zhou MJ, Haugland RP, Boxer LA, Petty HR. Oscillatory pericellular proteolysis and oxidant deposition during neutrophil locomotion. Biophys J. 1998;74(1):90-97.
55. Kao RC, Wehner NG, Skubitz KM, Gray BH, Hoidal JR. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J Clin Invest. 1988;82(6):1963-1973.
56. Shapiro SD, Endicott SK, Province MA, Pierce JA, Campbell EJ. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. J Clin Invest. 1991;87(5):1828-1834.
57. Hu TH, Tai DI, Changchien CS, Chen TY, Chang WC. Double pylorus: report of a longitudinal follow-up in two refractory cases with underlying diseases. Am J Gastroenterol. 1995;90(5):815-818.
58. Kuhn C, Yu SY, Chraplyvy M, Linder HE, Senior RM. The induction of emphysema with elastase. II. Changes in connective tissue. Lab Invest. 1976;34(4):372-380.
59. Sahebjami H, MacGee J. Changes in connective tissue composition of the lung in starvation and refeeding. Am Rev Respir Dis. 1983;128(4):644-647.
60. Kuhn C III, Starcher BC. The effect of lathyrogens on the evolution of elastase-induced emphysema. Am Rev Respir Dis. 1980;122(3):453-460.
61. Lesser M, Padilla ML, Cardozo C. Induction of emphysema in hamsters by intratracheal instillation of cathepsin B. Am Rev Respir Dis. 1992;145(3):661-668.
62. Damiano VV, Tsang A, Kucich U, et al. Immunolocalization of elastase in human emphysematous lungs. J Clin Invest. 1986;78(2):482-493.
63. Wang Z, Zheng T, Zhu Z, et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000;192(11):1587-1600.
64. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277(5334):2002-2004.
65. Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol. 2003;163(6):2329-2335.
66. Churg A, Wright JL. Proteases and emphysema. Curr Opin Pulm Med. 2005;11(2):153-159.
67. Owen CA. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(2):253-268.
68. Burnett D, Chamba A, Hill SL, Stockley RA. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet. 1987;2(8567):1043-1046.
69. Woolhouse IS, Bayley DL, Lalor P, Adams DH, Stockley RA. Endothelial interactions of neutrophils under flow in chronic obstructive pulmonary disease. Eur Respir J. 2005;25(4):612-617.
70. Sapey E, Stockley JA, Greenwood H, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(9):1176-1186.
71. Yoshioka A, Betsuyaku T, Nishimura M, Miyamoto K, Kondo T, Kawakami Y. Excessive neutrophil elastase in bronchoalveolar lavage fluid in subclinical emphysema. Am J Respir Crit Care Med. 1995;152(6 pt 1):2127-2132.
72. Subramanian DR, Jenkins L, Edgar R, Quraishi N, Stockley RA, Parr DG. Assessment of pulmonary neutrophilic inflam mation in emphysema by quantitative positron emission tomography. Am J Respir Crit Care Med. 2012;186(11):1125-1132.
73. Campbell EJ, Campbell MA, Boukedes SS, Owen CA. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. J Clin Invest. 1999;104(3):337-344.
74. Churg A, Zhou S, Wright JL. Series "matrix metalloproteinases in lung health and disease": matrix metalloproteinases in COPD. Eur Respir J. 2012;39(1):197-209.
75. Cerveri I, Corsico AG, Grosso A, et al. The rapid FEV(1) decline in chronic obstructive pulmonary disease is associated with predominant emphysema: a longitudinal study. COPD. 2013;10(1):55-61.
76. Haruna A, Muro S, Nakano Y, et al. CT scan findings of emphysema predict mortality in COPD. Chest. 2010;138(3):635-640.
77. Kim WJ, Wood AM, Barker AF, et al. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res. 2012;13:16.
78. Sapey E, Wood AM, Ahmad A, Stockley RA. Tumor necrosis factor alpha rs361525 polymorphism is associated with increased local production and downstream inflammation in COPD. Am J Respir Crit Care Med, 2010;15:182(2):192- 199.
79. McAloon CJ, Wood AM, Gough SC, Stockley RA. Matrix metalloprotease polymorphisms are associated with gas transfer in alpha 1 antitrypsin deficiency. Ther Adv Respir Dis. 2009;3(1):23-30.
80. Demeo DL, Campbell EJ, Barker AF, et al. IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency. Am J Respir Cell Mol Biol. 2008;38(1):114-120.
81. Lewis EC. Expanding the clinical indications for α(1)-antitrypsin therapy. Mol Med. 2012;18:957-970.